

TIROFIBAN

Class: Antiplatelet Agent, Glycoprotein IIb/IIIa Inhibitor

Indications: Treatment of acute coronary syndrome (ie, unstable angina/non-ST-elevation myocardial infarction [UA/NSTEMI]) in combination with heparin

Unlabeled: To support PCI (administered at the time of PCI) for ST-elevation myocardial infarction (STEMI), UA/NSTEMI, and stable ischemic heart disease (ie, elective PCI)

Available dosage form in the hospital: 0.25MG INJ

Dosage:

-Unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI): I.V.: Initial rate of 0.4 mcg/kg/minute for 30 minutes and then continued at 0.1 mcg/kg/minute. Dosing should be continued through angiography and for 12-24 hours after angioplasty or atherectomy.

-Percutaneous coronary intervention (PCI) (unlabeled use): I.V.: Loading dose: 25 mcg/kg over 3 minutes at the time of PCI; Maintenance infusion: 0.15 mcg/kg/minute continued for up to 18-24 hours .

Renal Impairment :

$Cl_{cr} < 30$ mL/minute: Reduce dose to 50% of normal rate.

Common side effect:

Cardiovascular: Coronary artery dissection (5%), bradycardia (4%), edema (2%). Central nervous system: Dizziness (3%), vasovagal reaction (2%), fever (>1%), headache (>1%). Gastrointestinal: Nausea (>1%)

Genitourinary: Pelvic pain (6%). Hematologic: Thrombocytopenia: $< 90,000/mm^3$ (1.5%), $< 50,000/mm^3$ (0.3%)

Pregnancy Risk Factor: B